Skip to content
PRLB

Proto Labs, Inc.

Proto Labs, Inc. Q2 FY2025 earnings call

July 31, 2025 · fiscal period ended 2025-06

EPS · actual vs est

$0.41 / $0.33Beat +24.2%

Revenue · actual vs est

$135.1M / $131.7MBeat +2.6%
Ask about this call

Summary

Generated 2025-07-31

Management highlights

  • Strong Q2 results with record revenue and EPS, exceeding expectations. - Received 2025 Future of Manufacturing Project Award. - Metal 3D printing service in Raleigh got ISO 13485 certification. - Customers using combined offer grew 44% YOY, revenue per customer up 11% QOQ. - Marketing investments driving engagement, sales enablement tools advanced, fulfillment channels optimized. - Tariffs impact margins temporarily but AI systems help adapt. - Focus on customer and employee experience, sharpening strategy and execution. - Priorities: drive growth in KPIs, expand production capabilities, reinforce core prototyping business.
View in transcript ↓

Segment performance

Second quarter revenue was a company record at $135.1 million, up 6.5% YOY in constant currencies and 7% sequentially. CNC machining revenue was a record, growing 20% YOY (30% growth in US). Injection Molding declined 4% YOY. 3D Printing was down 1% YOY due to prototyping weakness. Sheet Metal grew 9%. US revenue grew 12% YOY, while Europe revenue declined 15% in constant currencies. Consolidated Non-GAAP gross margin was flat sequentially at 44.8%, down 90 basis points YOY due to network revenue growth and tariff impacts.

View in transcript ↓

Guidance

  • Third quarter 2025 revenue expected between $130 million and $138 million, midpoint implies 6% growth YOY in constant currencies. - Foreign currency expected to have ~$400,000 favorable impact on revenue. - Non-GAAP EPS expected between $0.35 and $0.43 for Q3 2025.
View in transcript ↓

Risks

  • Tariffs and changing trade policies create short-term margin pressures. - Europe manufacturing contraction impacts revenue and margins.
View in transcript ↓

Q&A highlights

Q: Strength in CNC work, leaning toward production, prototyping, or both?

A: All of the above, combination of production and prototyping.

Q: Strength continuing into Q3 and July?

A: Midpoint of guidance indicates strength continuing in same areas.

Q: Injection Molding pressure, what's causing it and turnaround?

A: Weakness in medical, majority of Injection Molding through factory, network is small portion; innovating to win more production business.

Q: Tariffs impact on margin, quantification?

A: Tariffs on aluminum and steel affected network margins, adjusted pricing and fulfillment to offset, network margins back to pre-tariff levels by June.

Q: Network margin and A&D mix?

A: Network margin was 29% in quarter; A&D is north of 20% of business.

Q: 30 days visibility comment on network business?

A: 15% of network business has longer visibility, 85% has limited visibility.

Q: Seasonality in Q4?

A: Expect typical seasonality with Q3 to Q4 down slightly due to holiday periods.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$0.41$0.33+24.2%$0.38
Revenue$135.1M$131.7M+2.6%$125.6M

Transcript

July 31, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.